On December 19, 2022, ITI Limited, a wholly-owned subsidiary of Intra-Cellular Therapies, Inc. (the "Company"), reported that it has entered into Amendment No. 1 (the "Amendment") to the Master Services Agreement dated as of January 10, 2017 (the "MSA") by and between Lonza Ltd ("Lonza") and ITI Limited, to, among other items, extend the current term of the MSA until December 31, 2028 and provide for certain minimum annual purchase commitments by the Company for the years 2025 through 2028 for Lonza’s manufacture of CAPLYTA (Filing, 8-K, Intra-Cellular Therapies, DEC 19, 2022, View Source [SID1234625541]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which will be attached as an exhibit to the Company’s Annual Report on Form 10-K for the year ending December 31, 2022.